Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

被引：53

作者：

Ahmad, Javed ^{[1
,2
]}

Akhter, Sohail ^{[3
,4
]}

Rizwanullah, Md. ^{[5
]}

Khan, Mohammad Ahmed ^{[6
]}

Pigeon, Lucie ^{[4
]}

Addo, Richard T. ^{[7
]}

Greig, Nigel H. ^{[8
]}

Midoux, Patrick ^{[4
]}

Pichon, Chantal ^{[4
]}

Kamal, Mohammad Amjad ^{[9
,10
,11
]}

机构：

[1] NIPER, Dept Pharmaceut, Raebareli 229010, UP, India

[2] Najran Univ, Coll Pharm, Dept Pharmaceut, Najran, Saudi Arabia

[3] Ctr Val Loire Reg, LE STUDIUM Loire Valley Inst Adv Studies, Orleans, France

[4] CNRS, Ctr Biophys Mol, Nucle Acids Transfer Non Viral Methods, UPR4301, Orleans, France

[5] Jamia Hamdard, Dept Pharmaceut, Fac Pharm, New Delhi 110062, India

[6] Jamia Hamdard, Dept Pharmacol, Fac Pharm, New Delhi 110062, India

[7] Union Univ, Sch Pharm, Room 149 Providence Hall,1050 Union Univ Dr, Jackson, TN 38305 USA

[8] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH,Biomed Res Ctr, 251 Bayview Blvd, Baltimore, MD 21224 USA

[9] King Abdulaziz Univ, King Fahd Med Res Ctr, POB 80216, Jeddah 21589, Saudi Arabia

[10] Enzymoics, 7 Peterlee Pl, Hebersham, NSW 2770, Australia

[11] Novel Global Community Educ Fdn, Hebersham, Australia

来源：

CURRENT ALZHEIMER RESEARCH | 2017年 / 14卷 / 11期

基金：

美国国家卫生研究院;

关键词：

Alzheimer's disease; blood brain barrier; diagnosis; theranostic; nanoparticles; nanomedicines; BLOOD-BRAIN-BARRIER; CONVECTION-ENHANCED DELIVERY; CERIUM OXIDE NANOPARTICLES; LOADED PLGA NANOPARTICLES; AMYLOID-INDUCED TOXICITY; CENTRAL-NERVOUS-SYSTEM; DRUG-DELIVERY; IN-VITRO; COMPLEMENT ACTIVATION; GOLD NANOPARTICLES;

D O I：

10.2174/1567205014666170508121031

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

Background: Alzheimer's disease (AD), a cognitive dysfunction/dementia state amongst the elders is characterized by irreversible neurodegeneration due to varied pathophysiology. Up till now, anti-AD drugs having different pharmacology have been developed and used in clinic. Yet, these medications are not curative and only lowering the AD associated symptoms. Improvement in treatment outcome required drug targeting across the blood-brain barrier (BBB) to the central nervous system (CNS) in optimal therapeutic concentration. Nanotechnology based diagnostic tools, drug carriers and theranostics offer highly sensitive molecular detection, effective drug targeting and their combination. Over the past decade, significant works have been done in this area and we have seen very remarkable outocome in AD therapy. Various nanoparticles from organic and inorganic nanomaterial category have successfully been investigated against AD. Conclusion: This paper discussed the role of nanoparticles in early detection of AD, effective drug targeting to brain and theranostic (diagnosis and therapy) approaches in AD's management.

引用

页码：1164 / 1181

页数：18

共 149 条

[1]

Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits [J].